Efficacy News and Research

RSS

CRISPR activation library uncovers gene driving lymphoma growth and resistance

Researchers have uncovered a previously unknown gene causing resistance to a leading blood cancer drug and several genes that accelerate lymphoma growth by using a powerful new CRISPR activation library.

18 Sep 2026

NUS scientists harness magnetic pulses to reprogram immune cells to fight breast cancer

Researchers from the National University of Singapore (NUS) have demonstrated an innovative approach for targeted breast cancer therapy using pulsed electromagnetic fields (PEMFs).

18 Sep 2026

Experts call for eating-disorder screening before GLP-1 treatment

An international multidisciplinary panel developed consensus-based recommendations for GLP-1 receptor agonist use in people with eating disorders, calling for screening, individualized monitoring, patient education, and further research into safety and potential therapeutic effects. The experts cautioned that current evidence remains limited and inconsistent, particularly outside binge eating disorder, and identified major gaps in understanding the risk of new or recurrent eating disorders during treatment.

16 Sep 2026

Shatavari may affect more than hormones, and the gut could help explain why

A review in Nutrients examined how bioactive compounds in Asparagus racemosus (Shatavari) may influence cognitive health through the microbiota-gut-brain axis, estrogen-related signaling, neuroinflammation, oxidative stress, and neurotransmitter regulation. Evidence from computational, cellular, animal, and limited human studies suggests several plausible biological pathways, but key questions remain about bioavailability, brain exposure, dosing, and clinical efficacy.

16 Sep 2026

Cold plunges may boost your mood, but the evidence is still on thin ice

A Molecular Psychiatry review examined evidence linking cold exposure with mood and mental health outcomes, alongside proposed roles for catecholamines, the HPA axis, and immune-inflammatory pathways. Early studies report short-term mood improvements and physiological changes, but clinical evidence remains limited, and the proposed mechanisms have not been established as drivers of lasting psychiatric benefits.

16 Sep 2026

Wearable electroceutical platform enables remote wireless pain management

A "wearable electroceutical" has been developed that could reduce the need to visit a hospital or rely on painkillers every time pain occurs.

15 Sep 2026

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

European registry shows continued improvements in cataract surgery outcomes

A total of 363,039 cataract surgeries performed in 12 European countries in 2024 have been recorded in the European Registry of Quality Outcomes for Cataract and Refractive Surgery (EUREQUO), according to the latest figures presented at the 44th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) today (Tuesday).

14 Sep 2026

Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLC

Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated for small cell lung cancer (SCLC), according to results from the randomized Phase 2 DeLLphi-309 study presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Neoadjuvant atezolizumab addition quadruples pathological responses in resectable lung tumors

Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone, according to final results from the Phase 3 IMpower030 trial.

12 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Early studies hint that ketones may affect pathways linked to PTSD

An integrative review found that ketogenic therapy may influence metabolic, inflammatory, oxidative stress, and neurotransmitter pathways implicated in PTSD, with animal studies and small human studies reporting early signs of symptom improvement. Human evidence remains limited to very small cohorts, case reports, and pilot studies, and controlled trials have yet to establish clinical efficacy.

11 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

Tizanidine looked promising early in a migraine trial, but the benefit did not last

A randomized, double-blind, placebo-controlled trial found that low-dose tizanidine did not provide sustained reductions in headache burden over 12 weeks in people with episodic migraine, despite a transient improvement with the 1 mg dose at week 4. Exploratory analyses suggested that smoking and sex may influence tizanidine exposure, while sex-specific efficacy signals remained hypothesis-generating and require confirmation.

10 Sep 2026

Why researchers are looking at psilocybin for repeated mild head injuries

In female rats with repetitive mild head injury, psilocybin reduced acute imaging measures consistent with vasogenic edema and phosphorylated tau while altering vascular reactivity, functional connectivity, neurotrophic proteins, and lipid signaling. The findings provide preclinical evidence of potential therapeutic effects, but behavioral benefits were limited, and whether these biological changes translate into lasting neurological protection or benefits in humans remains unknown.

9 Sep 2026

Early B-cell therapy linked to better MS disease control

For people recently diagnosed with multiple sclerosis (MS), early treatment choices were associated with only slight differences after two years, based on the first treatment they used, according to a study published September 9, 2026, in Neurology Open Access, an official journal of the American Academy of Neurology.

9 Sep 2026

Study links methylglyoxal stress to immunotherapy resistance in triple-negative cancer

The metabolism of cancer cells may play a key role in their ability to evade the immune system. This is demonstrated by a new study conducted by researchers at the University of Liège, which reveals how methylglyoxal stress – a by-product of tumor metabolism – promotes immunosuppression and the formation of metastases, and may contribute to resistance to immunotherapy and the progression of triple-negative cancer.

9 Sep 2026

Digital companion apps help secure long-term habits during GLP-1 therapy

Glucagon-like peptide-1 (GLP-1) medications have revolutionized weight management, yet high dropout rates and rapid weight regain remain significant hurdles for many patients.

9 Sep 2026